Maviret package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Maviret (Glecaprevir / Pibrentasvir)

Prescription required

Maviret

Glecaprevir, Pibrentasvir

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Maviret (glecaprevir and pibrentasvir) is a hepatitis c virus ns3/4a protease inhibitor and hepatitis c virus ns5a inhibitor listed in our Medications for infections directory and prescribed for specified forms of hepatitis (2.1). Administered via the oral route, Maviret is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Maviret is a medication containing the active pharmaceutical ingredient glecaprevir and pibrentasvir, classified pharmacologically as a hepatitis c virus ns3/4a protease inhibitor and hepatitis c virus ns5a inhibitor (2.1). It is clinically indicated for the management of specified forms of hepatitis as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Medications for infections section of our catalogue, patients and prescribers frequently review Maviret alongside related therapies such as Acyclovir, Adefovir Dipivoxil, Albendazole, and Amoxicillin / Clavulanate Potassium.

Official Indications and Usage

Maviret is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). Mavyret is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both. (2.1)

Mechanism of Action and Pharmacology

Mechanism of Action mavyret is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral agents against the hepatitis C virus. (2.1)

What is Hepatitis?

Hepatitis means inflammation of the liver and has several causes. Viral hepatitis types differ in transmission, treatment, and monitoring. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Hepatitis condition guide for appointment questions and related therapies (2.1).

Ordering Maviret from Canada for U.S. Delivery

U.S. patients can order Maviret (Glecaprevir, Pibrentasvir) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Maviret
Chemical / Generic Name Glecaprevir And Pibrentasvir
Pharmacological Class Hepatitis C Virus NS3/4A Protease Inhibitor and Hepatitis C Virus NS5A Inhibitor
Therapeutic Category Medications for infections
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus
Routes of Administration Oral
Dosage Forms & Strengths Maviret is available as tablets or pellets for oral use. Tablets: pink, oblong-shaped, film-coated, and debossed with “nxt” on one side. Each tablet
Primary Indications Specified Forms Of Hepatitis
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier K6BUU8J72P, 2WU922TK3L
NLM RxNorm Concept ID (RxCUI) 1940703, 1940709, 2557906, 2557910
FDA Application License NDA215110
Official DailyMed SetID 7bf99777-0401-9095-8645-16c6e907fcc0
Catalogue Index Links Letter M Index · All Medications · All Categories

Directions

Dosage and Administration Overview

Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc. See recommended treatment duration for patients 3 years and older in tables below. Treatment-Naïve Patients 1 HCV Genotype Treatment Duration No Cirrhosis Compensated Cirrhosis (Child-Pugh A) 1, 2, 3, 4, 5, or 6 8 weeks 8 weeks Treatment-naïve patients are those who have not received treatment for the current infection. Treated with prior regimens containing ledipasvir and sofosbuvir or daclatasvir with (peg) interferon and ribavirin. (2.1)

Presentations and Strengths

Maviret is available as tablets or pellets for oral use. Tablets: pink, oblong-shaped, film-coated, and debossed with “nxt” on one side. Each tablet contains 100 mg glecaprevir and 40 mg of pibrentasvir. Oral pellets: pink and yellow coated pellets in unit-dose packets. Tablets: 100 mg glecaprevir and 40 mg pibrentasvir. (2.1)

Administration Guidance

Take Maviret orally at the same time(s) each day as directed on your prescription label (2.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.

Missed Dose Guidance

If you miss a scheduled dose of Maviret, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Maviret is glecaprevir and pibrentasvir (2.1).

Inactive Ingredients (Excipients)

According to the U.S. FDA product labeling, formulation excipients include colloidal silicon dioxide, copovidone (type K 28), croscarmellose sodium, hypromellose 2910, iron oxide red, lactose monohydrate, polyethylene glycol 3350, propylene glycol monocaprylate (type II), sodium stearyl fumarate, titanium dioxide, and vitamin E (tocopherol) polyethylene glycol succinate (2.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.

Cautions and important safety information

Boxed Warning

Warning: risk OF hepatitis B virus reactivation IN patients coinfected With HCV and HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with mavyret. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated. (2.1)

Contraindications

Maviret is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation. Mavyret is contraindicated with atazanavir or rifampin. Coadministration with atazanavir or rifampin. (2.1)

Key Clinical Precautions

Before starting or continuing Maviret, discuss your complete medical history with your healthcare provider. Key clinical cautions include (2.1):

  • Hepatic (liver) effects: Elevations in liver enzymes or rare cases of severe hepatic injury have been reported. Baseline and periodic liver function tests may be recommended; seek medical evaluation for jaundice, dark urine, or persistent right-upper-abdominal pain.
  • Hemorrhage and bleeding risk: Anticoagulant, antiplatelet, or gastrointestinal-affecting therapies can increase the risk of serious or fatal bleeding. Report unusual bruising, nosebleeds, blood in urine or stools, black tarry stools, or coughing up blood immediately.
  • Blood pressure elevation: Monitor blood pressure regularly during treatment and inform your clinician if sustained increases occur.

Pregnancy, Lactation, and Special Populations

No adequate human data are available to establish whether or not mavyret poses a risk to pregnancy outcomes. In animal reproduction studies, no adverse developmental effects were observed when the components of mavyret were administered separately during organogenesis at exposures up to 53 times (rats; glecaprevir) or 51 and 1.5 times (mice and rabbits, respectively; pibrentasvir) the human exposures at the recommended dose of mavyret. (2.1)

Interactions

Official Drug Interaction Overview

Carbamazepine, efavirenz, and St. John’s wort may decrease concentrations of glecaprevir and pibrentasvir. Coadministration of carbamazepine, efavirenz containing regimens, and St. John’s wort with mavyret is not recommended. Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. (2.1)

Important Interaction Categories

Concomitant use of Maviret with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Warfarin and vitamin K antagonists (such as Coumadin (Warfarin Sodium) or Warfarin Generic in our Cardiovascular directory): Concomitant administration may alter prothrombin time and International Normalized Ratio (INR) or have additive effects on hemostasis and bleeding risk. More frequent INR monitoring and clinical observation for bleeding are recommended.
  • Digoxin (such as Lanoxin (Digoxin) or Digoxin Generic): Co-administration can affect P-glycoprotein transport or renal clearance of digoxin, altering serum digoxin concentrations. Appropriate clinical and laboratory monitoring of digoxin levels is advised.
  • Cyclosporine and calcineurin inhibitors (such as cyclosporine or tacrolimus): Co-administration can alter drug transport (OATP1B1 or P-gp) or CYP metabolism, changing blood levels of either medication or increasing nephrotoxicity and myopathy risks.
  • Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.

Side effects

Like all medications, Maviret can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (2.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
  • Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.
  • Fatigue or tiredness: May occur during initial adjustment or dose changes.

Clinical Trial and Postmarketing Adverse Reactions

In subjects receiving mavyret, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of mavyret cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Overall Adverse Reactions in Subjects with Chronic HCV Infection without Cirrhosis or with Compensated Cirrhosis (Child-Pugh A) The adverse reactions data for mavyret in subjects without cirrhosis or with compensated cirrhosis (Child-Pugh A) were derived from nine registrational Phase 2 and 3 trials which evaluated approximately 2,300 adults infected with genotype 1, 2, 3, 4, 5, or 6 HCV who received mavyret for 8, 12 or 16 weeks. (2.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Tablets Configuration Content Package Size NDC Monthly carton (blister pack) 4 weekly cartons 7 daily blisters/carton 3 tablets/blister 84 tablets 0074-2625-04 Monthly carton (wallet) 4 weekly cartons 7 daily wallets/carton 3 tablets/wallet 84 tablets 0074-2625-28 8-Week Carton 2 monthly cartons 4 weekly cartons/monthly carton 7 daily wallets/carton 3 tablets/wallet 168 tablets 0074-2625-56 Bottle 84 tablets 0074-2625-84 mavyret tablets are pink-colored, film-coated, oblong biconvex shaped, debossed with “nxt” on one side. Store at or below 30°C (86°F). Mavyret Oral Pellets mavyret oral pellets are dispensed in child-resistant unit-dose packets in cartons. Each carton contains 28 packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir pink and yellow oral pellets. (2.1)

Store Maviret in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (2.1).

Frequently Asked Questions About Maviret

What is Maviret and what active ingredient does it contain?

Maviret is a hepatitis c virus ns3/4a protease inhibitor and hepatitis c virus ns5a inhibitor containing the active pharmaceutical ingredient glecaprevir and pibrentasvir. It is supplied for oral administration and requires a valid prescription where applicable.

How does Maviret work in the body?

Mechanism of Action mavyret is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral agents against the hepatitis C virus.

What conditions is Maviret prescribed to treat?

Maviret is primarily indicated for specified forms of hepatitis. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Maviret?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Maviret is administered via the oral route. Take or apply it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Maviret?

Commonly reported side effects of Maviret include feeling sick, vomiting, loose stools, headache, abdominal pain, and tiredness. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Maviret?

Important interaction categories for Maviret include warfarin, digoxin, cyclosporine, and medicines that strongly affect CYP3A enzymes. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Maviret be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Maviret to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Maviret online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Maviret (Glecaprevir, Pibrentasvir) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Maviret have a generic equivalent (Glecaprevir, Pibrentasvir) at a Canada pharmacy?

Currently, Maviret (Glecaprevir, Pibrentasvir) is dispensed in our catalogue as a brand-name formulation. Check our Glecaprevir, Pibrentasvir active ingredient hub for updates as licensed generic presentations become available.

How is Maviret shipped to U.S. residents, and how much does shipping cost?

Maviret ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Maviret prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Maviret prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to 1-888-804-1287. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Maviret (Glecaprevir / Pibrentasvir) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Mavyret. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) MedlinePlus Medical Encyclopedia: Hepatitis. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  3. (3.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help